Johnson & Johnson (JNJ)

Over the past six months, Johnson & Johnson's stock has experienced some fluctuations and notable events. As of June 2025, the six-month price total return for JNJ was -0.8%. Key events impacting the stock price include Q4 2024 earnings surpassing expectations but sales projections falling short, the Stelara patent expiration and biosimilar launches impacting sales, Q1 2025 earnings exceeding expectations and raising the full-year sales outlook, a dividend increase, the acquisition of Intra-Cellular Therapies, an $8 million verdict in a Talc Lawsuit, and positive clinical trial data for several investigational medicines.

While specific, detailed information on demand seasonality for all Johnson & Johnson products is not readily available, the company actively works to manage and predict demand. Johnson & Johnson has been transforming its demand planning function to improve forecast accuracy and optimize external manufacturing operations. This includes incorporating data like weather to better understand consumer buying patterns for products such as allergy medications. The company also experienced a significant spike in demand for its consumer products in some markets during the COVID-19 pandemic, highlighting how external events can influence demand.

Johnson & Johnson operates primarily in the healthcare sector, with its business divided into two main segments: Innovative Medicine and MedTech. The company spun off its consumer health business into a new publicly traded company, Kenvue, in 2023, to focus exclusively on prescription drugs and medical device technologies. The Innovative Medicine segment focuses on therapeutic areas such as immune disorders, cancer, neurological disorders, infectious diseases, and cardiovascular and metabolic diseases. The MedTech segment offers a wide range of products used in orthopedics, surgery, interventional solutions, and vision care.

Johnson & Johnson has a significant global presence, with products available in over 175 countries and operations in more than 60 countries. The company operates manufacturing units across the United States, Europe, Asia-Pacific, Africa, the Western Hemisphere (excluding the U.S.), and Latin America. Switzerland has been an important location for Johnson & Johnson since 1959, with various companies and over 5,600 employees.

Johnson & Johnson has maintained a strong brand value in the pharmaceutical sector, holding its top-ranking position for brand value for the sixth consecutive year as of June 2024, with a 5% increase in brand value to USD 13.4 billion. However, the company continues to face challenges related to its past legal issues, including an $8 million verdict against Johnson & Johnson in a Massachusetts Mesothelioma Talc Lawsuit in June 2025, where the jury found that the company concealed the dangers of its talc products.

Johnson & Johnson's ownership structure is primarily held by institutional investors, who hold approximately 73.57% of outstanding shares. Major institutional shareholders include The Vanguard Group, BlackRock, Inc., and State Street Corporation. Top individual shareholders include executive chairman Alex Gorsky, CEO Joaquin Duato, former chief scientific officer Paulus Stoffels, Jennifer Taubert, and CFO Joseph J. Wolk.